Volume 6, Issue 3: Understanding the Microbiology of the CF Lung
e-Cystic Fibrosis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Cystic Fibrosis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.
(Volume 6, Issue 3)
Nurses and health care professionals involved in the care of patients with Cystic Fibrosis.
After participating in this activity, the participant will demonstrate the ability to:
- Describe the complexity of the CF airway microbiome
- Summarize how the structure and activity of CF airway microbial communities affect lung disease progression
- Differentiate between culture-based and culture-independent assessment of CF airway microbiology
John J. LiPuma, MD
Professor of Pediatrics University of Michigan
Ann Arbor, Michigan
Dr. John LiPuma reports that he has served as a consultant for Raptor Pharma, Aradigm Corp, and CURx Pharma.
Dr. John LiPuma reports there will be no off-label or unapproved uses of any drugs.
- 0.50 ANCC
- 0.50 Attendance